PIAS 3 Antibody (E-3): sc-48339

PIAS 3 Antibody (E-3) is a mouse monoclonal IgG2a antibody that detects PIAS 3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-PIAS 3 antibody (E-3) plays a crucial role in studying the regulation of the STAT3 signaling pathway, which is vital for various cellular processes, including cell growth, survival, and differentiation. PIAS 3 (E-3) antibody enables research on STAT3 binding inhibition, helping scientists understand gene expression modulation in response to cytokine signaling. This interaction is particularly important in inflammatory responses and cancer research, where aberrant STAT3 activity can lead to uncontrolled cell proliferation and survival. PIAS 3 monoclonal antibody (E-3) supports investigation of STAT3 activity regulation, highlighting PIAS 3′s potential as a therapeutic target in diseases characterized by dysregulated cytokine signaling. PIAS 3 (E-3) monoclonal antibody facilitates research on protein interactions within the STAT signaling pathway, emphasizing PIAS 3′s significance in cellular signaling networks. With robust performance in various applications, anti-PIAS 3 antibody (E-3) serves as an essential tool for studying cytokine signaling and its implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PIAS 3 Antibody (E-3) References:

1. Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.  |  Ye, L., et al. 2010. PLoS One. 5: e9602. PMID: 20231901
2. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells.  |  Saydmohammed, M., et al. 2010. J Cell Biochem. 110: 447-56. PMID: 20235152
3. PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 activation.  |  Lee, SH., et al. 2014. Immunol Lett. 160: 79-88. PMID: 24718277
4. Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.  |  Dabir, S., et al. 2014. Clin Cancer Res. 20: 5124-32. PMID: 25124686
5. PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.  |  Abbas, R., et al. 2015. Cancer Med. 4: 325-32. PMID: 25573684
6. MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma.  |  Wang, C., et al. 2017. Sci Rep. 7: 41456. PMID: 28120918
7. Nuclear Smad6 promotes gliomagenesis by negatively regulating PIAS3-mediated STAT3 inhibition.  |  Jiao, J., et al. 2018. Nat Commun. 9: 2504. PMID: 29950561
8. PIAS3/SOCS1-STAT3 axis responses to oxidative stress in hepatocellular cancer cells.  |  Sun, H., et al. 2021. Am J Transl Res. 13: 12395-12409. PMID: 34956461
9. Protein inhibitor of activated STAT3 (PIAS3) attenuates psoriasis and associated inflammation.  |  Zhou, J., et al. 2023. J Dermatol. 50: 1262-1271. PMID: 37392066
10. Crosstalk between PKA and PIAS3 regulates cardiac Kv4 channel SUMOylation.  |  Jansen, LR., et al. 2024. Cell Commun Signal. 22: 422. PMID: 39223673

The preferred PIAS 3 antibody is PIAS 3 Antibody (C-12): sc-46682.